Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy

Regen BioPharma Inc

Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.
Company claims it is the first combination of immunotherapy and gene silencing in a single drug.
Technology uses aptamers (short DNA/RNA) to deliver gene-silencing sequences while inhibiting traditional immune checkpoints like PD-1.
CEO David Koos believes platform will yield numerous potent therapeutic candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.